Under the agreement, Adamis Pharma and Beximco Pharma plan to introduce four generic respiratory drug formulations in the US market over the next three years.
The two companies will co-develop certain generic formulations, some of which Beximco currently produces for the European market.
Adamis Pharma will be responsible for Food and Drug Administration (FDA) regulatory approval and marketing in the US.
Beximco Pharma managing director Nazmul Hassan said that they look forward to working closely with Adamis to capitalise on the generic drug opportunities in the US market, and achieving sustainable growth through creating long-term shareholder value.
Adamis Pharma president and CEO Dennis Carlo said that the two companies can capitalise on the notable synergies that exist between both organisations.